ENTRY       D01453                      Drug
NAME        Caffeine hydrate (JP18);
            Caffeine monohydrate;
            Caffeine (TN)
FORMULA     C8H10N4O2. H2O
EXACT_MASS  212.0909
MOL_WEIGHT  212.2059
SOURCE      Coffea arabica [TAX:13443]
CLASS       Respiratory system agent
             DG01616  Xanthine derivative
              DG01612  Xanthine-type central nervous system stimulant
            Metabolizing enzyme substrate
             DG01892  CYP1A2 substrate
             DG02855  CYP2E1 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2115
            ATC code: D11AX26 N06BC01
            Chemical structure group: DG00974
            Product (DG00974): D00528<JP> D01453<JP> D07603<US>
            Product (mixture): D12295<US>
EFFICACY    Stimulant (central), Adenosine receptor antagonist, Phosphodiesterase inhibitor
COMMENT     Xanthine derivative
TARGET      ADORA1 [HSA:134] [KO:K04265]
            ADORA2A [HSA:135] [KO:K04266]
            PDE [HSA:5153 5138 5139 5140 5141 5142 5143 5144 8654] [KO:K13755 K18283 K19021 K13296 K13293 K13762]
  PATHWAY   hsa04020(135+5153)  Calcium signaling pathway
            hsa04024(134+135+5139+5140+5141+5142+5143+5144)  cAMP signaling pathway
            hsa04080(134+135)  Neuroactive ligand-receptor interaction
            hsa04270(135)  Vascular smooth muscle contraction
METABOLISM  Enzyme: CYP1A2 [HSA:1544]; CYP3A4 [HSA:1576], CYP2E1 [HSA:1571]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AX Other dermatologicals
                 D11AX26 Caffeine
                  D01453  Caffeine hydrate (JP18) &lt;JP&gt;
             N NERVOUS SYSTEM
              N06 PSYCHOANALEPTICS
               N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
                N06BC Xanthine derivatives
                 N06BC01 Caffeine
                  D01453  Caffeine hydrate (JP18) &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               211  Cardiotonics
                2115  Caffeines
                 D01453  Caffeine hydrate (JP18)
            Classification of Japanese OTC drugs [BR:br08313]
             Agents for nervous and sensory systems
              05 Alertness drug
               D01453  Caffeine hydrate (JP18)
            Risk category of Japanese OTC drugs [BR:br08312]
             Third-class OTC drugs
              Inorganic and organic chemicals
               Anhydrous caffeine
                D01453  Caffeine hydrate (JP18)
            Drug groups [BR:br08330]
             Respiratory system agent
              DG01616  Xanthine derivative
               DG01612  Xanthine-type central nervous system stimulant
                DG00974  Caffeine
                 D01453  Caffeine hydrate
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00974  Caffeine
                D01453  Caffeine hydrate
              DG02855  CYP2E1 substrate
               DG00974  Caffeine
                D01453  Caffeine hydrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00974  Caffeine
                 D01453  Caffeine hydrate
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Adenosine
                ADORA1
                 D01453  Caffeine hydrate (JP18) &lt;JP&gt;
                ADORA2A
                 D01453  Caffeine hydrate (JP18) &lt;JP&gt;
             Enzymes
              Hydrolases (EC3)
               Phosphodiesterases
                PDE
                 D01453  Caffeine hydrate (JP18) &lt;JP&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D01453  Caffeine hydrate
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D01453
            Drug groups [BR:br08330]
             Respiratory system agent
              DG01616  Xanthine derivative
               DG01612  Xanthine-type central nervous system stimulant
                DG00974  Caffeine
             Metabolizing enzyme substrate
              DG01892  CYP1A2 substrate
               DG00974  Caffeine
              DG02855  CYP2E1 substrate
               DG00974  Caffeine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00974  Caffeine
DBLINKS     CAS: 5743-12-4
            PubChem: 7848516
            ChEBI: 31332
            LigandBox: D01453
            NIKKAJI: J244.705C
ATOM        15
            1   O0  O    24.1379  -11.5446
            2   C8y C    16.6622  -10.8171
            3   C8y C    16.6622  -12.2416
            4   C8y C    17.8649  -10.1105
            5   N4y N    15.3601  -10.3850
            6   N4y N    17.8649  -12.9248
            7   N5x N    15.3601  -12.6737
            8   N4y N    19.0852  -10.8462
            9   O5x O    17.8649   -8.7325
            10  C8x C    14.5428  -11.5409
            11  C8y C    19.0852  -12.1892
            12  C1a C    17.8649  -14.3553
            13  C1a C    20.3055  -10.1632
            14  O5x O    20.3347  -12.8898
            15  C1a C    14.9204   -9.0467
BOND        15
            1     2   3 2
            2     2   4 1
            3     2   5 1
            4     3   6 1
            5     3   7 1
            6     4   8 1
            7     4   9 2
            8     5  10 1
            9     6  11 1
            10    6  12 1
            11    8  13 1
            12   11  14 2
            13    7  10 2
            14    8  11 1
            15    5  15 1
///
